Qianyi Wang1, Hong You1, Xiaojuan Ou1, Xinyan Zhao1, Yameng Sun1, Min Wang1, Ping Wang1, Yu Wang1, Weijia Duan1, Xiaoming Wang1, Shanshan Wu2, Yuanyuan Kong2, Romil Saxena3, Annette S H Gouw4, Jidong Jia5. 1. Liver Research Center, Beijing Friendship Hospital, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing, 100050, China. 2. Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China. 3. Indiana University Health Pathology Laboratory, Department of Pathology, Indiana University School of Medicine, 350 West 11th Street, #4014, Indianapolis, IN, 46202, USA. rsaxena@iupui.edu. 4. Department of Pathology and Medical Biology, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. a.s.h.gouw@umcg.nl. 5. Liver Research Center, Beijing Friendship Hospital, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing, 100050, China. jia_jd@ccmu.edu.cn.
Abstract
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) commonly affects subjects with obesity, yet non-obese NAFLD is increasingly being recognized. We aimed to investigate the clinicopathological and genetic characteristics of non-obese NAFLD patients. METHODS: The clinical, histological and genetic data of 84 NAFLD patients with biopsy for abnormal liver function test were reviewed. Both NAS-CRN and SAF scoring systems were applied for histopathological evaluation. PNPLA3 and TMS6F2 genotyping were also performed. RESULTS: All of the 84 patients were histologically diagnosed with non-alcoholic steatohepatitis (NASH), with 36 of them (42.9%) being non-obese (BMI < 25 kg/m2). Compared with the obese group, non-obese group were predominantly females (88.9% vs 52.1%, p < 0.001), tended to have higher prevalence of diabetes (p = 0.068). More importantly non-obese patients had a significant higher prevalence of advanced fibrosis (F ≥ 3) (58.3% vs 29.2%, p = 0.013), and a trend of higher degree of ballooning (p = 0.061). In addition, values of liver stiffness measurement were also significantly higher in non-obese group (12.1 kPa vs 8.1 kPa, p = 0.032). There was also a trend of higher prevalence of TM6SF2 T allele in non-obese group (p = 0.085), while the prevalence of PNPLA3 risk allele did not differ between two groups. Multivariate analysis showed that higher fasting glucose (p = 0.038) and lower serum platelets (p = 0.040) were two independent predictors for advanced fibrosis in non-obese patients. CONCLUSIONS: Non-obese NASH patients have a female predominance and more advanced fibrosis. Liver biopsy is crucial to evaluate the severity of disease in non-obese patients especially those with abnormal liver biochemistry. CLINICAL TRIAL NUMBER: NCT03386890.
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) commonly affects subjects with obesity, yet non-obese NAFLD is increasingly being recognized. We aimed to investigate the clinicopathological and genetic characteristics of non-obese NAFLD patients. METHODS: The clinical, histological and genetic data of 84 NAFLD patients with biopsy for abnormal liver function test were reviewed. Both NAS-CRN and SAF scoring systems were applied for histopathological evaluation. PNPLA3 and TMS6F2 genotyping were also performed. RESULTS: All of the 84 patients were histologically diagnosed with non-alcoholic steatohepatitis (NASH), with 36 of them (42.9%) being non-obese (BMI < 25 kg/m2). Compared with the obese group, non-obese group were predominantly females (88.9% vs 52.1%, p < 0.001), tended to have higher prevalence of diabetes (p = 0.068). More importantly non-obese patients had a significant higher prevalence of advanced fibrosis (F ≥ 3) (58.3% vs 29.2%, p = 0.013), and a trend of higher degree of ballooning (p = 0.061). In addition, values of liver stiffness measurement were also significantly higher in non-obese group (12.1 kPa vs 8.1 kPa, p = 0.032). There was also a trend of higher prevalence of TM6SF2 T allele in non-obese group (p = 0.085), while the prevalence of PNPLA3 risk allele did not differ between two groups. Multivariate analysis showed that higher fasting glucose (p = 0.038) and lower serum platelets (p = 0.040) were two independent predictors for advanced fibrosis in non-obese patients. CONCLUSIONS: Non-obese NASH patients have a female predominance and more advanced fibrosis. Liver biopsy is crucial to evaluate the severity of disease in non-obese patients especially those with abnormal liver biochemistry. CLINICAL TRIAL NUMBER: NCT03386890.
Authors: E Bonora; G Targher; M Alberiche; R C Bonadonna; F Saggiani; M B Zenere; T Monauni; M Muggeo Journal: Diabetes Care Date: 2000-01 Impact factor: 19.112
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Yang-Lin Liu; Helen L Reeves; Alastair D Burt; Dina Tiniakos; Stuart McPherson; Julian B S Leathart; Michael E D Allison; Graeme J Alexander; Anne-Christine Piguet; Rodolphe Anty; Peter Donaldson; Guruprasad P Aithal; Sven Francque; Luc Van Gaal; Karine Clement; Vlad Ratziu; Jean-Francois Dufour; Christopher P Day; Ann K Daly; Quentin M Anstee Journal: Nat Commun Date: 2014-06-30 Impact factor: 14.919
Authors: Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George Journal: Nat Rev Gastroenterol Hepatol Date: 2022-06-16 Impact factor: 73.082
Authors: Mircea Vasile Milaciu; Ștefan Cristian Vesa; Ioana Corina Bocșan; Lorena Ciumărnean; Dorel Sâmpelean; Vasile Negrean; Raluca Maria Pop; Daniela Maria Matei; Sergiu Pașca; Andreea Liana Răchișan; Anca Dana Buzoianu; Monica Acalovschi Journal: J Clin Med Date: 2019-12-13 Impact factor: 4.241
Authors: Alejandro Campos-Murguía; Astrid Ruiz-Margáin; José A González-Regueiro; Ricardo U Macías-Rodríguez Journal: World J Gastroenterol Date: 2020-10-21 Impact factor: 5.742
Authors: Leonardo Ruiz-Casas; Gabriel Pedra; Anum Shaikh; Bethany Franks; Harpal Dhillon; João Diogo da Rocha Fernandes; Kamal Kant Mangla; Margarida Augusto; Jörn M Schattenberg; Manuel Romero-Gómez Journal: Medicine (Baltimore) Date: 2021-12-17 Impact factor: 1.817